- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01438424
Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials
19 lipca 2012 zaktualizowane przez: Bristol-Myers Squibb
A Preliminary Assessment of Safety and Antiviral Activity of Open-label Entecavir in Subjects With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials
The purpose of this study is to provide entecavir to participants who have completed another entecavir trial without achieving virologic response or who relapsed during postdosing follow-up.
Przegląd badań
Status
Zakończony
Warunki
Interwencja / Leczenie
Typ studiów
Interwencyjne
Zapisy (Rzeczywisty)
1053
Faza
- Faza 2
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
16 lat i starsze (Dziecko, Dorosły, Starszy dorosły)
Akceptuje zdrowych ochotników
Nie
Płeć kwalifikująca się do nauki
Wszystko
Opis
Key inclusion criteria:
- Age of 16 years and older
- Receipt of entecavir or lamivudine in a previous entecavir study.
Participants who were, based on their response to entecavir:
- Virologic nonresponders at Week 48
- Partial virologic responders who became nonresponders during the second year of treatment
- Partial virologic responders at Week 96
Complete responders who relapsed during postdosing follow-up
- Decompensated liver disease in AI463-048 that met 1 or more of the following criteria:
- Nonresponse to adefovir after at least 24 weeks of treatment
- Partial response to adefovir after 96 weeks of treatment
- Complete response to adefovir after relapsing during postdosing follow-up
Demonstrated intolerance to adefovir
- Except for those participants enrolled from AI463-048, compensated liver disease.
Key exclusion criteria:
- HIV coinfection
- Receiving nephrotoxic or hepatotoxic agents
- Ongoing opportunistic infections
- Hemoglobin level <11.0 g/dL except for those enrolled from AI463-048
- Platelet count <70,000 mm^3 except for those enrolled from AI463-048
- Absolute granulocyte count <1,500 cells/mm^3
- Recent history of pancreatitis (within 24 weeks prior to first dose of therapy)
- Current evidence of ascites requiring paracentesis, hepatic encephalopathy, or variceal bleeding, except for those enrolled from AI463-048
- Known history of allergy to nucleoside analogues.
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Entecavir, 1.0 mg, with or without lamivudine
|
Tablets, Oral, 1.0 mg, once daily
Inne nazwy:
Oral, 100 mg, daily
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Overall Study: Number of Participants With Death As Outcome, Any Adverse Event (AE), Grade 3-4 AEs, Serious Adverse Events (SAEs), and Discontinuations Due to AEs
Ramy czasowe: Continuously from Day 1 through Week 240
|
An AE is a new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not be causally related to treatment.
An SAE is an unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling.
ALT=alanine transaminase; ULN=upper limit of normal.
|
Continuously from Day 1 through Week 240
|
Overall Study: Number of Participants With Normal Hematology Values at Baseline and Abnormalities in Hematology Laboratory Test Results Through Week 240
Ramy czasowe: Day 1 of treatment through Week 240
|
Hemoglobin (g/dL): Grade (Gr) 1=9.5-11.0;
Gr 2=8.0-<9.5;
Gr 3=6.5-<8.0;
Gr 4=<6.5 White blood cells (cells/mm^3): Gr 1=2,500-<4,000; Gr 2=1,000-<2,500; Gr 3=800-<1,000; Gr 4=<800.
Neutrophils (cells/mm^3): Gr 1=1000-<1500; Gr 2=750-<1000; Gr 3=500-<750; Gr 4=<500.
Platelets (cells/mm^3): Gr 1=75,000-99,000; Gr 2=50,000-<75,000; Gr 3=20,000-<50,000; Gr 4=<20,000.
Prothrombin time (seconds): Gr 1=1.01-<1.26*ULN;
Gr 2=1.26-<1.51
*ULN; Gr 3=1.51-3*ULN;
Gr 4=>3*ULN.
INR: Gr 1=1.24-1.5;
Gr 2=1.5-2;
Gr 3=2-3; Gr 4=>3.
INR=international normalized ratio; ULN=upper limit of normal. .
|
Day 1 of treatment through Week 240
|
Overall Study: Number of Participants With Normal Pancreatic Enzyme and Renal Function Values at Baseline and Abnormalities in Pancreatic Enzyme and Renal Function Laboratory Test Results at End of Dosing
Ramy czasowe: Day 1 of treatment through Week 240
|
Amylase: Grade 1=1.10-<1.40*ULN;
Grade 2=1.40-< 2.10*ULN; Grade 3=2.10-5.00*ULN;
Grade 4=>5.00*ULN.
Lipase: Grade 1.1-<1.4*ULN;
Grade 2=1.4-<2.1*ULN;
Grade 3=2.1-5.0*ULN;
Grade 4=>5.0*ULN.
Creatinine: Grade 1=1.10-< 1.60*ULN; Grade 2=1.60-<3.10*ULN;
Grade 3=3.10-6.00*ULN;
Grade 4=>6.00*ULN.
Blood urea nitrogen (BUN): Grade 1=1.25-<2.60*ULN;
Grade 2=2.60-<5.10*ULN;
Grade 3=5.10-10*ULN;
Grade 4=>10*ULN.
ULN=upper limit of normal.
|
Day 1 of treatment through Week 240
|
Overall Study: Number of Participants With Normal Electrolyte and Fasting Glucose Values at Baseline and Abnormalities in Electrolyte and Fasting Glucose Laboratory Test Results at End of Dosing
Ramy czasowe: Day 1 of treatment through Week 240
|
Hypochloremia: Grade (Gr) 1=90-93; Gr 2=85-<90; Gr 3=80-<85; Gr 4=40-<80.
Hyperchloremia: Gr 1=113-<117; Gr 2=117-<121; Gr 3=121-125; Gr 4>125.
Hypocarbia: Gr 1=19-21; Gr 2=15-<19; Gr 3=41-45; Gr 4=>45.
Hypercarbia: Gr 1=31-36; Gr 2=37-40; Gr 3=41-45; Gr 4=>45.
Hyponatremia: Gr 1=130-132; Gr 2=123-<130; Gr 3=116-<123; Gr 4<116.
Hypernatremia: Gr 1=148-<151; Gr 2=151-<158; Gr 3=158-165; Gr 4=>165.
Hypokalemia: Gr 1=3-3.4;
Gr 2=2.5-<3;
Gr 3=2-<2.5;
Gr 4=<2.
Hyperkalemia: Gr 1=5.6-<6.1;
G2=6.1-<6.6;
Gr 3=6.6-7;
Gr 4=>7.
Hypoglycemia: Gr 1=55-64; Gr 2=40-<55; Gr 3=30-< 40; G4=-<30.
Hyperglycemia: Gr 1=116-<161; Gr 2=161-<251; Gr 3=251-500; Gr 4>500.
|
Day 1 of treatment through Week 240
|
Week 144: Number of Participants With Death As Outcome, Any AE, Grade 3-4 AEs, SAEs, Discontinuations Due to AEs, and Abnormalities in Selected Laboratory Test Results
Ramy czasowe: Continuously from Day 1 through Week 144
|
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment.
An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling.
AST=aspartate aminotransferase; ULN=upper limit of normal.
|
Continuously from Day 1 through Week 144
|
Week 192: Number of Participants With Death As Outcome, Any AE, Grade 3-4 AEs, SAEs, Discontinuations Due to AEs, and Abnormalities in Selected Laboratory Test Results
Ramy czasowe: Continuously from Day 1 through Week 192
|
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment.
An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
CTC Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling.
ALT=alanine aminotransferase; ULN=upper limit of normal.
|
Continuously from Day 1 through Week 192
|
Off-treatment Follow-up: Percentage of Participants With Sustained Hepatitis B Virus (HBV) DNA <10,000 Copies by Polymerase Chain Reaction (PCR) Assay (Amendment 11 Cohort)
Ramy czasowe: End of dosing to Week 48 off-treatment follow-up
|
The Amendment 11 Cohort consisted of participants who were hepatitis B e antigen (HBeAg) negative and who had compensated liver disease, a minimum of 192 weeks (4 years) of treatment with entecavir, HBV DNA <300 copies/mL by PCR assay for ≥48 weeks before end of dosing and on the last observed result ≤24 weeks prior to end of dosing, and serum ALT levels ≤1.0*ULN at the end of study drug dosing.ALT=alanine aminotransferase; ULN=upper limit of normal.
|
End of dosing to Week 48 off-treatment follow-up
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Overall Study: Percentage of Participants With Sustained HBV DNA Level <300 Copies/mL by PCR Assay
Ramy czasowe: Study entry to Week 192
|
Study entry to Week 192
|
|
Overall Study: Percentage of Participants With Sustained HBV DNA <10^4 Copies/mL by PCR Assay
Ramy czasowe: Study entry to Week 192
|
Study entry to Week 192
|
|
Overall Study: Percentage of Participants by HBV DNA Category by PCR Assay
Ramy czasowe: Baseline to Week 192
|
Observed values.
|
Baseline to Week 192
|
Overall Study: Mean HBV DNA Level by PCR Assay
Ramy czasowe: Study entry to Week 216
|
Study entry to Week 216
|
|
Overall Study: Percentage of Participants Who Achieved a Loss of Hepatitis B e Antigen (HBeAg)
Ramy czasowe: Study entry to Week 216
|
Observed values.
|
Study entry to Week 216
|
Overall Study: Percentage of Participants With HBeAg Seroconversion
Ramy czasowe: Study entry to Week 216
|
Observed values.
Seroconversion=negative HBeAg with detectable anti-HBe antibody.
|
Study entry to Week 216
|
Overall Study: Mean Alanine Transaminase (ALT) Levels
Ramy czasowe: Study entry to Week 216
|
Observed values.
|
Study entry to Week 216
|
Overall Study: Percentage of Participants Who Achieved ALT Normalization
Ramy czasowe: Study entry to Week 216
|
ULN=upper limit of normal.
ALT normalization=ALT levels ≤1.0*ULN.
|
Study entry to Week 216
|
Week 192: Percentage of Participants With Histologic Improvement (Efficacy Evaluable Cohort)
Ramy czasowe: Baseline to Week 192
|
The Knodell Histologic Activity Index scores stage of necrosis and grade of inflammation in liver biopsies.
Components are necrosis near the portal vein, intralobular degeneration and focal necrosis, portal inflammation, and fibrosis.
The 4 components are scored from 1 to 4 and 1 to 10 (necrosis near the portal vein) and combined for a total score, with 22 being the highest possible score.
Higher the score for each component=greater liver damage.
Histologic improvement=a ≥2-point reduction in total Knodell score and no worsening in fibrosis.
Cohort participants had to have adequate baseline and long-term biopsy samples and baseline Knodell necroinflammatory scores ≥2.
|
Baseline to Week 192
|
Week 192: Percentage of Participants With Improvement in Fibrosis (Efficacy Evaluable Cohort)
Ramy czasowe: Baseline to Week 192
|
The Ishak Modification for Hepatic Activity Index (HAI) scores necroinflammatory activity in chronic hepatitis.
0=no fibrosis, 1=fibrosis expansion of some portal areas, 2=fibrosis expansion of most portal areas, 3=fibrosis expansion of most portal areas with occasional bridging, 4=fibrosis expansion of portal areas with marked bridging, 5=incomplete cirrhosis, 6=probable or definite cirrhosis.
Higher score=more severe necrosis.
Improvement in fibrosis=≥1-point reduction in HAI score.
Cohort participants had to have adequate baseline and long-term biopsy samples and baseline Knodell scores ≥2.
|
Baseline to Week 192
|
Overall Study: Percentage of Participants With a Confirmed ≥1 log10 Increase From Nadir in HBV DNA by PCR Assay
Ramy czasowe: Baseline to Week 144
|
Baseline to Week 144
|
|
Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay, Loss of HBeAG, Seroconversion, and ALT ≤1.0*Upper Limit of Normal (ULN) (Entecavir Continuous Treatment Cohort)
Ramy czasowe: Baseline to Weeks 48, 96, 144, 192, and 240
|
The Entecavir Continuous Treatment Cohort consisted of participants from study AI463-022 (NCT00035633) who were nucleoside-naive HBeAg-positive and enrolled in the current study with ≤35 days off treatment between the last dose in AI463-022 and the first dose in the current.
This cohort is considered to be on continuous entecavir treatment and permitted assessment of continuous administration of entecavir in AI463-022 and the current study.
|
Baseline to Weeks 48, 96, 144, 192, and 240
|
Percentage of Participants Who Achieved HBV DNA <300 and <10^4 Copies/mL by PCR Assay and ALT ≤1.0*Upper Limit of Normal (ULN) (Entecavir Retreatment Cohort)
Ramy czasowe: Baseline to Weeks 48, 96, and 144
|
The Entecavir Retreatment Cohort consisted of participants who were nucleoside-naive, HBeAg-negative and enrolled from BMS study AI463-027 with >60 days off treatment between the last dose in AI463-027 and the first dose in the current study.
This cohort permitted assessment of entecavir, 1.0 mg, provided as retreatment in the current study.
|
Baseline to Weeks 48, 96, and 144
|
Week 96: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay, Loss of HBeAg, HBeAg Seroconversion, and ALT ≤1.0*ULN (Lamivudine Continuous Switch Cohort)
Ramy czasowe: Baseline to Week 96
|
The Lamivudine Continuous Switch Cohort consisted of participants who were nucleoside-naive, HBeAg-positive and received lamivudine in BMS study AI463-022 (NCT00035633) and enrolled in the current study with ≤35 days off treatment between end of dosing in AI463-022 and the switch to entecavir in the current study.
This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.
|
Baseline to Week 96
|
Week 144: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ≤1.0*ULN (Lamivudine Continuous Switch Cohort)
Ramy czasowe: Baseline to Week 144
|
The Lamivudine Continuous Switch Cohort consisted of participants who were nucleoside-naive, HBeAg-positive and received lamivudine in BMS study AI463-022 (NCT00035633) and enrolled in the current study with ≤35 days off treatment between end of dosing in AI463-022 and the switch to entecavir in the current study.
This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.
|
Baseline to Week 144
|
Week 96: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ≤1.0*ULN (Lamivudine Retreatment Switch Cohort)
Ramy czasowe: Baseline to Week 96
|
The Lamivudine Retreatment Switch Cohort consisted of participants who were nucleoside-naive HBeAg negative and enrolled from BMS study AI463-027 (NCT00035789) with >60 days between end of dosing in AI463-027 and the switch to entecavir in the current study.
This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.
|
Baseline to Week 96
|
Week 144: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ≤1.0*ULN (Lamivudine Retreatment Switch Cohort)
Ramy czasowe: Baseline to Week 144
|
The Lamivudine Retreatment Switch Cohort consisted of participants who were nucleoside-naive HBeAg negative and enrolled from BMS study AI463-027 (NCT00035789) with >60 days between end of dosing in AI463-027 and the switch to entecavir in the current study.
This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.
|
Baseline to Week 144
|
Off-treatment Follow-up: Percentage of Participants With Sustained HBV DNA <1,000, <300, and <10,000 Copies/mL by PCR Assay and With ALT ≤1*ULN (Amendment 11 Cohort)
Ramy czasowe: End of dosing to Weeks 48 and 96 off-treatment follow-up
|
The Amendment 11 Cohort consisted of participants who were HBeAg negative and who had compensated liver disease, a minimum of 192 weeks (4 years) of treatment with entecavir, HBV DNA <300 copies/mL by PCR Assay for ≥48 weeks before end of dosing and on the last observed result ≤24 weeks prior to end of dosing, and serum ALT levels ≤1.0*ULN at the end of study drug dosing.
ULN=upper limit of normal.
|
End of dosing to Weeks 48 and 96 off-treatment follow-up
|
Off-treatment Follow-up: Mean Change in HBV DNA (Amendment 11 Cohort)
Ramy czasowe: End of dosing to Weeks 48 and 96 off-treatment follow-up
|
The Amendment 11 Cohort consisted of participants who were HBeAg negative and who had compensated liver disease, a minimum of 192 weeks (4 years) of treatment with entecavir, HBV DNA <300 copies/mL by PCR assay for ≥48 weeks before end of dosing and on the last observed result ≤24 weeks prior to end of dosing, and serum ALT levels ≤1.0*ULN at the end of study drug dosing.
|
End of dosing to Weeks 48 and 96 off-treatment follow-up
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Publikacje i pomocne linki
Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów
1 stycznia 2001
Zakończenie podstawowe (Rzeczywisty)
1 grudnia 2009
Ukończenie studiów (Rzeczywisty)
1 kwietnia 2011
Daty rejestracji na studia
Pierwszy przesłany
16 września 2011
Pierwszy przesłany, który spełnia kryteria kontroli jakości
21 września 2011
Pierwszy wysłany (Oszacować)
22 września 2011
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
23 sierpnia 2012
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
19 lipca 2012
Ostatnia weryfikacja
1 lipca 2012
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby Układu Pokarmowego
- Zakażenia wirusem RNA
- Choroby wirusowe
- Infekcje
- Infekcje przenoszone przez krew
- Choroby zakaźne
- Choroby wątroby
- Zapalenie wątroby, wirusowe, ludzkie
- Infekcje Hepadnaviridae
- Infekcje wirusami DNA
- Infekcje enterowirusowe
- Infekcje Picornaviridae
- Zapalenie wątroby, przewlekłe
- Zapalenie wątroby typu B
- Zapalenie wątroby
- Wirusowe Zapalenie Wątroby typu A
- Wirusowe zapalenie wątroby typu B, przewlekłe
- Molekularne mechanizmy działania farmakologicznego
- Środki przeciwinfekcyjne
- Środki przeciwwirusowe
- Inhibitory odwrotnej transkryptazy
- Inhibitory syntezy kwasów nukleinowych
- Inhibitory enzymów
- Agenci przeciw HIV
- Środki przeciwretrowirusowe
- Entekawir
- Lamiwudyna
Inne numery identyfikacyjne badania
- AI463-901
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na HBV
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Duke-NUS Medical School (Singapore)Jeszcze nie rekrutacja
-
Centre de Recherches et d'Etude sur la Pathologie...Zakończony
-
Aucta Pharmaceuticals, IncZakończony
-
Institute of Liver and Biliary Sciences, IndiaWycofane
-
Yi-Hua ZhouThe First People's Hospital of Kunshan; Taixing People's Hospital; Fourth People... i inni współpracownicyZakończony
-
West China HospitalRekrutacyjnyTransplantacja Nerki | HBVChiny
-
RenJi HospitalJeszcze nie rekrutacjaHBV | Zaburzenia przeszczepu wątroby
-
Fudan UniversityAktywny, nie rekrutującyHBV | PO PRZESZCZEPIENIU WĄTROBYChiny
-
Kaohsiung Medical University Chung-Ho Memorial...Rekrutacyjny
Badania kliniczne na Entecavir
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...NieznanyPrzewlekłe wirusowe zapalenie wątroby typu BBangladesz
-
Assembly BiosciencesZakończonyPrzewlekłe wirusowe zapalenie wątroby typu BStany Zjednoczone, Kanada, Hongkong, Nowa Zelandia, Zjednoczone Królestwo
-
Hanyang UniversityRoche Pharma AGNieznanyWirusowe zapalenie wątroby typu B, przewlekłeRepublika Korei